Dr. Pusztai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 George St, New Haven
Suite 120
New Haven, CT 06520Fax+1 203-785-5792
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986
Certifications & Licensure
CT State Medical License 2012 - 2025
TX State Medical License 1997 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2003
Clinical Trials
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Start of enrollment: 2001 Jan 01
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMolecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Faiza Yasin, Ethan Sokol, Neil Vasan, Dean C Pavlick, Richard S P Huang
The Oncologist. 2024-12-06 - Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer
Journal of Clinical Oncology. 2024-12-02 - Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer.Vignesh Gunasekharan, Hao-Kuen Lin, Michal Marczyk, Alejandro Rios-Hoyo, Gerson Espinoza Campos
Breast Cancer Research and Treatment. 2024-12-01
Journal Articles
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast CancerLajos Pusztai, MD, JAMA Network Open
- Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...Lajos Pusztai, Jose Baselga, JAMA
Lectures
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Why Do We Care About Molecular Evolution in Breast Cancer?2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 2013 Breast Cancer Symposium,American Society of Breast Surgeons, San Francisco, California - 9/7/2013
Press Mentions
Stand-Alone Adjuvant Immunotherapy for Early TNBC?November 22nd, 2024- Popular Weight Loss Drugs Now for Patients with Cancer?September 30th, 2024
- Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
